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A B S T R A C T
While the presence and abundance of the major oxysterols and cholestenoic acids in the circulation is well
established, minor cholesterol metabolites may also have biological importance and be of value to investigate. In
this study by observing the metabolism of deuterium-labelled cholesterol in the pdgfbret/ret mouse, a mouse
model with increased vascular permeability in brain, and by studying the sterol content of plasma from the
CYP46A1 transgenic mouse overexpressing the human cholesterol 24S-hydroxylase enzyme we have been able to
identify a number of minor cholesterol metabolites found in the circulation, make approximate-quantitative
measurements and postulate pathways for their formation. These “proof of principle” data may have relevance
when using mouse models to mimic human disease and in respect of the increasing possibility of treating human
neurodegenerative diseases with pharmaceuticals designed to enhance the activity of CYP46A1 or by adeno-
associated virus delivery of CYP46A1.
1. Introduction
Oxysterols are oxidised forms of cholesterol, or of its precursors
[1,2]. There is a growing interest in these molecules based on their
biological activities as ligands to, or modulators of, nuclear receptors
[3–7], G protein-coupled receptors (GPCRs) [8–13], of N-methyl-D-as-
partate receptors (NMDARs) [14] and of cholesterol biosynthesis,
through binding to INSIG (insulin induced gene) [15]. Cholestenoic
acids, i.e. acidic oxysterols, have been ascribed neuroprotective or
neurotoxic properties depending on their structures [16,17], are also
ligands to nuclear receptors [16,18,19], and the ultimate metabolites of
oxysterols, i.e. bile acids, are also biologically active as ligands to nu-
clear receptors [20–23] and GPCRs [24]. Both oxysterols and choles-
tenoic acids represent transport forms of cholesterol, transporting sterol
to the liver for further metabolism or excretion via the bile. By ad-
ministration of deuterated cholesterol to a healthy human volunteer
metabolic relationships between diﬀerent oxysterols and cholestenoic
acids have been established [25,26], but extensive studies with deut-
erated cholesterol have yet to be made on laboratory animals [27,28].
In human and mouse circulation the dominating oxysterols include
4β-hydroxycholesterol (4β-HC), 7α-hydroxycholesterol (7α-HC), 24S-
hydroxycholesterol (24S-HC), (25R)26-hydroxycholesterol (26-HC, also
known as 27-HC, see Supplemental Table S1 for common and sys-
tematic names of sterols) [29–31], formed from cholesterol by the cy-
tochrome P450 (CYP) enzymes CYP3A4, 7A1, 46A1 and 27A1, re-
spectively [32–35]. Minor oxysterols formed from cholesterol
precursors include 24S,25-epoxycholesterol (24S,25-EC) generated
from CYP46A1 oxidation of desmosterol, or via a shunt pathway in
parallel to cholesterol biosynthesis [36,37], cholesterol-7,8-epoxide
(7,8-EC) and 7-oxocholesterol (7-OC, also known as 7-ketocholesterol)
both formed by CYP7A1 oxidation of 7-dehydrocholesterol (7-DHC)
[38,39]. 7α-HC and 7-OC can also be formed via non-enzymatic reac-
tions from cholesterol, as may 7β-hydroxycholesterol (7β-HC), while
5,6-epoxycholesterol (5,6-EC) has to-date only been reported to be
formed via non-enzymatic reactions [40].
In human and mouse circulation, and in cerebrospinal ﬂuid (CSF),
the cholestenoic acids 3β-hydroxycholest-5-en-(25R)26-oic (3β-HCA)
and 7α-hydroxy-3-oxocholest-4-en-(25R)26-oic acid (7αH,3O-CA, 25R
stereochemistry is assumed unless indicated otherwise) are abundant,
so is 3β,7α-dihydroxycholest-5-en-(25R)26-oic acid (3β,7α-diHCA) in
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human but not in mouse [16,19,26,31,41–44].
Interestingly, increasing the cerebral activity of CYP46A1 has been
suggested to have therapeutic potential towards neurodegenerative
disease. Mast at al. have proposed CYP46A1 as a pharmacological
target for Alzheimer’s disease (AD) [45], while Burlot et al. have shown
that adeno-associated virus (AAV) delivery of CYP46A1 to an AD mouse
model rescued cognitive defects associated with the model [46].
Boussicault et al. found a similar AAV-CYP46A1 delivery to reduce
neuronal atrophy and motor defects in a mouse model of Huntington’s
disease [47]. On the other hand, inhibition of CYP27A1, the enzyme
required to introduce the (25R)26-carboxylate group into the choles-
terol skeleton, has been suggested as a potential therapeutic towards
age-related neurodegenerative disease and also breast cancer [48].
Importantly, Mast et al have shown that a number of existing phar-
maceutical drugs can inhibit CYP27A1 [49].
One way to learn more about the metabolic origin of diﬀerent
oxysterols and cholestenoic acids is to monitor their formation in vivo
from deuterated cholesterol. This approach has previously been
adopted to investigate the formation of a number of cholestenoic acids
in man and of oxysterols in man and rodents [25–27]. In this way
Meaney at al. deﬁned diﬀerent metabolic pathways from cholesterol to
3β,7α-diHCA and 7αH,3O-CA in man, where the initial oxidation of
cholesterol to 3β-HCA on its way to 3β,7α-diHCA is likely to be pul-
monary, while hepatic oxidation of cholesterol to 7α-HC is likely to be
the ﬁrst step in the pathway towards 7αH,3O-CA [26]. Whether, or not,
a similar disparity of pathways exists in mouse has yet to be established.
To investigate metabolic pathways further, knockout mice can be stu-
died and it was in this way the enzymes required to biosynthesise nu-
merous diﬀerent oxysterols were established [50,51]. An additional
genetic tool is to overexpress sterol metabolising enzymes in a trans-
genic (tg) mouse. This strategy has been adopted in mice over-
expressing human CYP27A1 or CYP46A1 [52,53].
Here, to investigate whether the metabolic relationships established
in man are similar to those found in mouse we have performed an ex-
tended analysis of the oxysterol and cholestenoic acid content of
plasma, utilising more speciﬁc and sensitive methods than previously
available, to extract additional metabolic information about oxysterols
and cholestenoic acids from a unique isotope experiment on a mouse
with a leaking blood-brain barrier [28] and a mouse model with
overexpressed CYP46A1 and high levels of 24S-hydroxycholesterol in
the circulation [53]. Admittedly, the low number of animals used in this
study is a limitation, however, our intention is to identify existing
minor metabolic pathways without evaluating their importance. We are
aware that more animals would be required in order to evaluate the
importance of the new pathways. We use a derivatisation strategy
called enzyme-assisted derivatisation for sterol analysis (EADSA),
where sterols with a 3β-hydroxy-5-ene structure are oxidised with
cholesterol oxidase to 3-oxo-4-ene sterols and then derivatised with the
Girard P (GP) hydrazine reagent [54–56] for liquid chromatography
(LC) - mass spectrometry (MS) with multistage fragmentation (MSn)
analysis. This greatly increases the sensitivity for sterol analysis and
aids in structure identiﬁcation through LCeMS and MSn. Sterols with a
native oxo group are derivatised with GP reagent in the absence of
cholesterol oxidase. To allow analysis via a single LC–MS(MSn) injec-
tion we use diﬀerent isotopic forms of GP reagent. [2H5]GP was used
with cholesterol oxidase treated sterols and [2H0]GP for derivatisation
in the absence of cholesterol oxidase (see Supplemental Fig. S1).
2. Materials and methods
2.1. Animals
Male tg mice overexpressing human CYP46A1 (CYP46A1tg) were as
described in Shafaati et al [53] and were from the study previously
reported by Saeed et al [28]. In addition, a single male pdgfbret/ret
mouse bred on a C56BL/6 background was fed for 40-days on a chow
diet containing 0.3% [26,26,26,27,27,27-2H6]cholesterol. This animal
was used in the previous study of Saeed et al as a pericyte-deﬁcient
mouse model to investigate the eﬀect of a leaking blood brain barrier
(BBB) on cholesterol metabolism in brain [28]. Male, wild type (WT)
mice were 12 weeks old C57BL/6 J from the Jackson Laboratory, US.
All experimental procedures in this study were in compliance with
National Institutes of Health Guide for Care and Use of Laboratory
Animals, the European Communities Council Directive of 24 November
1986 (86/609/EEC) and approved by The Northern Stockholm Re-
search Animal Ethics Committee.
2.2. Materials
Stable-isotope labelled oxysterols [25,26,26,26,27,27,27-2H7]7α-
HC ([2H7]7α-HC), [25,26,26,26,27,27,27-2H7]22R-hydroxycholesterol
([2H7]22R-HC), [25,26,26,26,27,27,27-2H7]24R/S-HC ([2H7]24R/S-
HC), [26,26,26,27,27,27-2H6]7α,25-dihydroxycholesterol ([2H6]7α,25-
diHC) and [25,26,26,26,27,27,27-2H7]cholesterol were from Avanti
Polar Lipids (Al, USA). [25,26,26,26,27,27,272H7]22R-Hydroxycholest-
4-en-3-one ([2H7]22R-HCO) was prepared by cholesterol oxidase
treatment of [2H7]22R-HC. 3β,7α,24S-Trihydroxycholest-5-en-(25R)
26-oic acid (3β,7α,24S-triHCA) was also from Avanti Polar Lipids.
Other oxysterols and cholestenoic acids were from previous studies or
as indicated in Supplemental Table S1 [54–56]. [2H0]GP was from TCI
Europe (Belgium), [2H5]GP was synthesised as described in Crick et al
[55]. Cholesterol oxidase enzyme from Streptomyces sp was from Sigma
– Aldrich (now Merck) UK.
2.3. Extraction of oxysterols and cholestenoic acids from plasma
Plasma (20 – 100 μL) was added dropwise to ethanol (1.05mL)
containing internal standards [2H7]24R/S-HC, [2H7]22R-HCO, [2H7]
7α-HC (20 ng each), [2H6]7α,25-diHC (2 ng) and [2H7]cholesterol
(20 μg), with sonication. For studies performed on mice fed [2H6]cho-
lesterol in the diet, [2H7]24R/S-HC and [2H7]cholesterol were omitted
from the internal standard mixture to avoid possible isotope overlap
with [2H6]cholesterol and its metabolic products. Water was added to
make-up the solution to 1.5mL of 70% ethanol. After further sonication
(5min) the solution was centrifuged (17,000 g for 30min) to remove
any precipitated matter.
To separate cholesterol from more polar oxysterols and cholestenoic
acids, to avoid the potential generation of cholesterol autoxidation ar-
tefacts during sample handling, the supernatant from above was loaded
onto a washed (4mL ethanol) and conditioned (6mL 70% ethanol)
200mg Certiﬁed Sep-Pak C18 solid phase extraction (SPE) column
(Waters UK). The ﬂow-through (1.5 mL) was combined with a column
wash (5.5 mL 70% ethanol) to give SPE1-Fr-1 (7mL 70% ethanol) rich
in oxysterols and cholestenoic acids. The column was washed with a
further 4mL of 70% ethanol to give SPE1-Fr-2, before cholesterol, and
sterols of similar polarity, were eluted from the column with 2mL of
ethanol to give SPE1-Fr-3. Each fraction was then divided into two
equal proportions (a) and (b) and dried under vacuum.
2.4. Enzyme-assisted derivatisation for sterol analysis (EADSA)
Oxysterols and cholestenoic acids were derivatised using EADSA
technology as described previously (Supplemental Fig. S1) [54–56]. In
brief, fraction SPE1-Fr-1(a) was re-dissolved in propan-2-ol (100 μL).
Phosphate buﬀer (50mM, pH 7, 1mL) containing cholesterol oxidase
enzyme (3 μL, 2mg/mL in water, 44 u/mg protein) from Streptomyces sp
was added and the mixture left for 1 h at 37 °C. The reaction was
quenched with 2mL of methanol. Glacial acetic acid (150 μL) was
added followed by [2H5]GP reagent (190mg as the bromide salt). After
vortexing the derivatisation reaction was allowed to proceed overnight
in the dark. Next morning, excess derivatisation reagent was removed
by SPE on a 60mg Oasis HLB column (Waters UK), previously washed
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with methanol (6mL), 10% methanol (6mL) and conditioned with 70%
methanol (4mL). The derivatisation mixture (3.25mL, 70% organic)
was loaded on the column followed by a 1mL wash (70% methanol) of
the reaction vessel. The column was rinsed and conditioned with 35%
methanol (1 mL) and the combined eﬄuent (5.25 mL) diluted with
water (4mL) to give a 35% methanol solution. This solution was re-
cycled through the column and the procedure repeated to give a 17.5%
methanol solution which was once more re-cycled through the column.
At this point all GP-derivatised oxysterols and cholestenoic acids are
extracted by the column and unreacted GP-reagent eluted to waste. The
column was ﬁnally washed with 10% methanol (6 mL) and derivatised
oxysterols, cholestenoic acids and other sterols eluted in 3× 1mL of
100% methanol and 1mL of ethanol. Oxysterols and cholestenoic acids
elute in the ﬁrst two 1mL fractions of methanol which were combined
to give SPE2-Fr-1+ 2(a). The entire procedure was repeated for SPE1-
Fr-1(b), but in the absence of cholesterol oxidase and using [2H0]GP
(150mg, chloride salt) rather than [2H5]GP, to give SPE2-Fr-1+ 2(b).
SPE2-Fr-1+ 2(a) was then combined with SPE2-Fr-1+ 2(b) diluted to
60% methanol and immediately analysed by LC–MS(MS)n.
2.5. LC–MS(MSn)
LC–MS(MSn) was performed using an Ultimate 3000 LC system
(Dionex, now Thermo Fisher Scientiﬁc, UK) linked to an Orbitrap Velos
(Thermo Scientiﬁc) linear ion trap (LIT) – Orbitrap hybrid mass spec-
trometer via an electrospray probe. The chromatographic separation
was on a reversed phase Hypersil Gold C18 column (1.9 μm,
50 x 2.1mm, Thermo Fisher Scientiﬁc) utilising a methanol/acetoni-
trile/formic acid gradient at ﬂow-rate 200 μL/min. Mobile phase A was
33.3% methanol, 16.7% acetonitrile containing 0.1% formic acid.
Mobile phase B was 63.3% methanol, 31.7% acetonitrile containing
0.1% formic acid. The gradient employed is indicated in Supplemental
Table S2.
For each injection up-to 5 scan events were performed. One high-
resolution scan was performed in the Orbitrap (60,000 FWHM deﬁni-
tion at m/z 400) in parallel to 2–4 MSn scans in the LIT. For MS2 nor-
malised collision energy was 30% and for MS3 35%. Sterols were
identiﬁed based on measurement of accurate mass (± 5 ppm), MS3
spectra and retention time, with comparison to authentic standards (see
Supplemental Tables 1 and 3). In the absence of authentic standards
presumptive identiﬁcations were based on these three parameters and
are described in detail in Supplemental Text. Quantiﬁcation was via
high-resolution MS based on known amounts of added internal stan-
dard. The internal standard utilised for each analyte is indicated in
Supplemental Tables S1 and S3. Previous studies have shown that side-
chain oxysterols once derivatised with GP-hydrazine give an equivalent
response factor [57]. Calibration curves showing a linear relationship
between peak area and concentration have been reported earlier [55].
Strictly speaking, sterols, other than side-chain oxysterols and other
oxysterols for which an authentic isotope-labelled standard was used,
are approximately quantiﬁed in this study.
2.6. Calculation of enrichment in deuterium
Enrichment in deuterium of sterol S is calculated as the percent of
the total species S present i.e.
% Enrichment in deuterium = ([2Hn]S / ([2Hn]S + [1H]S)) (1)
The “corrected value” for enrichment in deuterium is calculated
using eq. 2.
% Corrected Enrichment in Deuterium = % Enrichment in deuterium
for sterol S / % Enrichment in deuterium in cholesterol (2)
3. Results and discussion
3.1. Oxysterols and cholestenoic acids derived from [2H6]cholesterol
Our ﬁrst experiment was to investigate the diﬀerent pools of cho-
lesterol from which diﬀerent oxysterols and cholestenoic acids are de-
rived. This was achieved by feeding a single male pdgfbret/ret mouse
with a diet rich in [2H6]cholesterol for 40 days [28]. The pdgfbret/ret
mouse is a pericyte-deﬁcient model with enhanced BBB permeability
allowing an increased eﬄux of 24S-HC from brain. This facilitates the
measurement of brain derived cholesterol metabolites in plasma, al-
though the import of some cholesterol from the circulation to brain will
result in an increased deuterium content of brain derived metabolites
[28]. Our earlier study [28] showed the incorporation of deuterium in
brain cholesterol after 40 days of feeding of the mouse was about 7%,
corresponding to replacement of about 10% of brain cholesterol with
plasma cholesterol under the conditions used. Some results from this
earlier study have been reported previously, speciﬁcally for 24S-HC and
24R-HC following alkaline hydrolysis [28]. We now report new results
for non-esteriﬁed (no alkaline hydrolysis) oxysterols and cholestenoic
acids.
3.1.1. Oxysterols
Of the oxysterols known to be formed via enzymatic mechanisms
from cholesterol, 7α-HC, 7α-hydroxycholest-4-en-3-one (7α-HCO) and
7α,(25R)26-dihydroxycholest-4-en-3-one (7α,26-diHCO) were found to
be enriched with deuterium at a level of about 70%, equivalent to that
of cholesterol reported earlier (Fig. 1 and Supplemental Table S1) [28].
This indicates that after the 40-day period these three oxysterols have
been turned-over entirely i.e. deuterium enrichment is equivalent to
that of cholesterol. 7-OC was also enriched with deuterium to about
70%, but an enzyme converting cholesterol to 7-OC has not been
identiﬁed. It can, however, be formed via non-enzymatic mechanisms,
which probably account for its formation in e.g. Niemann Pick disease
type C [58–61], and perhaps here also. Alternatively, 7-OC can be
formed via oxidation of 7β-HC in a reaction catalysed by hydro-
xysteroid dehydrogenase 11B2 (HSD11B2) [12]. 7β-HC is not known to
be formed via an enzymatic reaction from cholesterol, but like 7-OC is
formed endogenously in lysosomal storage diseases, presumably via
non-enzymatic reactions [60,61]. However, when analysing 7β-HC and
7-OC there is always a risk that they may be formed, at least in part, by
ex vivo autoxidation of cholesterol [1]. This is likely to be true in this
study as the degree of deuterium enrichment of 7β-HC (95%) was
greater than that of cholesterol (70%).
The degree of deuterium enrichment in 24S-HC, 26-HC and 25-hy-
droxycholesterol (25-HC) was about 10%, 50% and 60%, respectively
(Fig. 1). The reduced degree of deuterium enrichment compared to
cholesterol and its 7-oxygenated products (Fig. 2) suggests diﬀerent
origins in terms of pools of cholesterol for these side-chain hydro-
xylated sterols. When evaluating deuterium enrichment of oxysterols it
is important to consider the deuterium isotope eﬀect, where the
breaking of a carbon-deuterium bond in the rate-determining step of a
reaction mechanism will slow down the reaction. As a consequence of
the deuterium isotope eﬀect, hydroxylation at C-26 is reduced in
[26,26,26,27,27,27-2H6]cholesterol compared to [2H0]cholesterol
[28,62] and this can account for some of the reduced deuterium en-
richment in 26-HC, but not in 25-HC or 24S-HC. It is interesting to note
that a deuterium isotope eﬀect does not appear to be evident in the
formation of 7α,26-diHCO. This indicates that CYP27A1, the sterol
(25R)26-hydroxylase, does not participate in the rate-determining step
in the biosynthesis of 7α,26-diHCO, which is most likely formed via 7α-
HC or 7α-HCO (Fig. 3). We have shown previously that 24-HC in mouse
consists of two epimers, 24S-HC and 24R-HC, and that 80% of 24S-HC
(measured after saponiﬁcation of oxysterol esters) in the circulation is
derived from brain while the remaining 20% and the entire 24R-epimer
are derived from extracerebral sources [28]. This is consistent with the
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data from the current study for non-esteriﬁed 24S-HC where only 10%
is found to be deuterated, compared to 70% for cholesterol. Taking this
into account we calculate that about 85% of 24S-HC found in the cir-
culation is derived from the non-exchangeable pool of cholesterol lo-
calised behind the BBB in brain. Here we can also conﬁrm that the 24R-
HC epimer is deuterated to a similar level as cholesterol, indicating its
extracerebral formation.
Minor peaks observed in the LC–MS(MS)n analysis of mouse plasma
correspond to a 3β,x-dihydroxycholest-5-en-y-one (3β,x-diHC-yO) and
x-hydroxycholest-4-ene-3,y-dione (x-HC-3,y-diO), possibly 3β,20-dihy-
droxycholest-5-en-22-one (3β,20-diHC-22O) and 20-hydroxycholest-4-
ene-3,22-dione (20-HC-3,22-diO) or the 22-hydroxy-24-oxo isomers i.e.
3β,22-diHC-24O and 22-HC-3,24-diO (Fig. 4A and Supplemental Fig.
S4A). These oxysterols are found to be hexadeuterated indicating an
absence of oxidation on the terminal carbon atom of the side-chain,
while the MS3 spectra suggest hydroxylation and carbonylation of the
side-chain. See Supplemental Text for a detailed description of identi-
ﬁcations from MS3 spectra. A third oxysterol also found to be hex-
adeuterated gave an MS3 spectrum of a 3β,x,y-trihydroxycholest-5-en-z-
one (triHCO), possibly 3β,22,25-trihydroxycholest-5-en-24-one
(3β,22,25-triHC-24O, Fig. 4B, Supplemental Fig. S4B). These three
oxysterols were deuterated to about 40–60% indicating that they are
not formed behind the BBB and with intact hexadeuteration, no deu-
terium isotope eﬀect is possible (Supplemental Table S1).
3.1.2. Cholestenoic acids
3β-HCA is biosynthesised from cholesterol via CYP27A1 catalysed
oxidation, this requires the removal of three hydrogen atoms from C-26
(Fig. 3). Thus, when [26,26,26,27,27,27-2H6]cholesterol is the sub-
strate, synthesis of 3β-HCA is attenuated as a consequence of the deu-
terium isotope eﬀect. The result is reduced incorporation of deuterium
into 3β-HCA i.e. 30% cf. 50% in 26-HC and 70% in cholesterol (Fig. 1,
Supplemental Table S1, Fig. 4A).
Unlike 3β-HCA, the deuterium incorporation into 7αH,3O-CA and
3β,7β-dihydroxycholest-5-en(25R)26-oic acid (3β,7β-diHCA) is at
about 65%, quite similar to that of cholesterol at 70%. This suggests
that these two acids are derived in mouse from cholesterol via a dif-
ferent pathway to 3β-HCA and/or from a diﬀerent pool of cholesterol
(Fig. 3). While only CYP27A1 is involved in the biosynthesis 3β-HCA;
CYP27A1, CYP7A1 or CYP7B1 and HSD3B7 are utilised to synthesise
7αH,3O-CA (Fig. 3). The similarity of deuterium incorporation in
7αH,3O-CA, 7α,26-diHCO, 7α-HCO and 7α-HC, and an absence of
3β,7α-diHCA in mouse plasma, suggests initial hydroxylation is at po-
sition 7α by CYP7A1, followed by oxidation at C-3 by HSD3B7, fol-
lowed by oxidation at C-26 by CYP27A1 (Fig. 3). Meaney et al, also
studying metabolism of deuterium-labelled cholesterol have suggested
a similar pathway to be operative in man [26]. The origin of 3β,7β-
diHCA is uncertain. The 7β-hydroxy group may be introduced by re-
duction of a 7-oxo group by HSD11B1 [63–65], which may be derived
by non-enzymatic oxidation of cholesterol at C-7 or enzymatic oxida-
tion of 7-DHC by CYP7A1, with CYP27A1 using either 7-oxo or 7β-
hydroxycholesterol as a substrate to generate 3β,7β-diHCA (Supple-
mental Fig. S5). Alternatively, 7β-HC may be introduced by non-enzy-
matic oxidation of cholesterol. Again, the high degree of enrichment of
deuterium in 3β,7β-diHCA suggests CYP27A1 is not involved in a rate-
determining step. In human, Shoda et al have suggested that 7α-
Fig. 1. Deuterium enrichment in diﬀerent oxysterols. The enrichment in cholesterol, reported in [28], is indicated by the dotted line.
P.J. Crick, et al. Journal of Steroid Biochemistry and Molecular Biology 195 (2019) 105475
4
hydroxy-5-ene sterols can be converted to their 7β-hydroxy equivalents
via a mitochondrial enzyme in liver [66], while the intestinal ﬂora may
prove an alternative route to 7α/7β-epimerisation [67].
7αH,3O-CA is found as both 25R and 25S epimers in human and
mouse [68–70], the 25S-epimer is formed by action of the α-methyl
acyl-CoA racemase (AMACR) enzyme on the 25R-CoA thioester in the
peroxisome (Fig. 3) [71], in plasma this is usually the minor epimer.
There is only a minor (about 5%) diﬀerence in the degree of enrichment
of deuterium in the two epimers.
3.1.3. Dihydroxyoxocholestenoic acids
In the analysis of mouse plasma two distinct dihydroxyox-
ocholestenoic acids are evident (Fig. 1, Fig. 5), but with quite diﬀerent
degrees of enrichment of deuterium. The identity of these two acids was
not immediately obvious. The latter eluting acid was more abundant
and deuterium enrichment was about 70%. This acid was previously
observed to be abundant in plasma of the Amacr knock-out (-/-) mouse
[69], suggesting that it is the 25R epimer and that the two hydroxy
groups are at 7α and 12α on a 3-oxocholest-4-en-(25R)26-oic acid
skeleton i.e. an intermediate in the biosynthesis of cholic acid (Fig. 3).
The MS3 spectra recorded of the non-deuterated and deuterated acids
were entirely compatible with this assignment (Supplemental Fig. S6C,
see also Supplemental Text) [72]. The degree of enrichment of deu-
terium of 7α,12α-dihydroxy-3-oxocholest-4-en-26-oic acid (7α,12α-
diH,3O-CA) was similar to that of 7αH,3O-CA, but diﬀerent to that of
3β-HCA, indicating that 7α,12α-diH,3O-CA is formed in an extension to
the pathway to 7αH,3O-CA, where CYP27A1 does not participate in the
rate-determining step. CYP8B1 is the sterol 12α-hydroxylase which will
hydroxylate 7α-hydroxysterols and is involved in the biosynthesis of
cholic acid [50].
The earlier eluting dihydroxyoxocholestenoic acid was enriched
with deuterium to a much lesser extent than 7α,12α-diH,3O-CA at only
20% cf. 70% (Fig. 1, Fig. 5). This suggests that it is formed from a
diﬀerent pool of cholesterol than the other 7α-hydroxy acids, or alter-
natively, CYP27A1 participates in the rate-determining step and the
deuterium isotope eﬀect accounts for the low-degree of enrichment of
deuterium. Side-chain shortening of cholestenoic and cholestanoic
acids proceeds via thioesteriﬁcation with CoA, then 24-hydroxylation,
further 24-oxidation and ultimately beta-oxidation of the acyl-CoA
thioester (Fig. 3). Thioesteriﬁcation by bile acid CoA synthetase (BACS,
Slc27a5) or by very long chain fatty-acyl-CoA ligase (or synthetase,
VLCS, Slc27a2) proceeds in the peroxisome or mitochondria, then in the
peroxisome the (25R)acyl-CoA thioester is ﬁrst converted to its 25S
epimer by AMARC, then oxidised by acyl-CoA oxidase 2 (ACOX2) to
give a 24-unsaturated thioester which is then 24-hydroxylated followed
by 24-dehydrogenation via the enzymes of D-bifunctional protein
(DBP), or in its absence, via L-bifunctional protein (LBP) [69,73]. With
EADSA methodology we tend to observe the free acid rather than the
acyl-CoA thioester. Alternatively, the oxysterol 24S-HC may provide the
source of the 24-hydroxy group for side-chain shortening (Fig. 3) [69].
Fig. 2. 24S-HC and 26-HC show low levels of enrichment of deuterium in comparison to 24R-HC, 7α-HC and 7α-HCO. (A) Reconstructed ion chromatograms (RICs)
for the [M]+ ions of [2H0] (m/z 539.4368, upper panel), [2H5] (m/z 544.4682, central panel), [2H6] (m/z 545.4744, lower panel) monohydroxysterols. (B) RICs as in
(A) but over the retention time range for “side-chain” monohydroxycholesterols. (C) TICs for the [M]+→[M-Py]+→ transitions for [2H0] (539.4→455.4→, upper
panel), [2H5] (544.5→460.4→, central panel), [2H6] (545.5→461.4→) over the retention time range for “side-chain” monohydroxycholesterols. (D) Multiple re-
action monitoring (MRM) transitions [M]+→[M-Py]+→353.3 for [2H0] (539.4→455.4→353.3, upper panel), [2H5] (544.5→460.4→353.3, central panel) and [2H6]
(545.5→461.4 →353.3, lower panel) isotopologues targeting 24-HC epimers. Labels are colour coded according to deuterium enrichment on a rainbow scale. Note
[2H6] and [2H5] isotopologues elute slightly before their [2H0] analogues. See Supplemental Fig. S2 for MS3 spectra and Supplemental Fig. S3 for fragment-ion
structures. The potential for autoxidation of cholesterol during sample preparation is discussed in reference [85].
P.J. Crick, et al. Journal of Steroid Biochemistry and Molecular Biology 195 (2019) 105475
5
Fig. 3. Biosynthetic route from cholesterol towards bile acids.
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In which case, if the early eluting dihydroxyoxocholestenoic acid is
7α,24S-dihydroxy-3-oxocholest-4-en-(25R)26-oic acid (7α,24S-diH,3O-
CA(25R)) the degree of enrichment of deuterium is likely to be similar
to that of 24S-HC, where enrichment of deuterium is much less than for
7α-hydroxysterols on account of 24S-HC being derived from non-ex-
changeable pool of cholesterol isolated behind the BBB.
To conﬁrm or not the identity of the lightly deuterium enriched
early eluting dihydroxyoxocholestenoic acid as 7α,24S-diH,3O-
CA(25R) we analysed plasma from the CYP46A1tg mouse over ex-
pressing human CYP46A1 (see section 3.2 below). As is evident from
Fig. 6, a chromatographic peak is very prominent in plasma from the
CYP46A1tg mouse with a similar retention time to the early eluting
dihydroxyoxocholestenoic acid in Fig. 5. Identiﬁcation of this acid as
7α,24-diH,3O-CA was made via comparison of retention time and MS3
spectrum with the authentic standard prepared by cholesterol oxidase
treatment of 3β,7α,24S-trihydroxycholest-5-en-(25R)26-oic acid, re-
cently custom synthesised by Avanti Polar Lipids. However, as is
evident from Fig. 3, 7α,24-diH,3O-CA can exist as 24R,25R, 24S,25S
and 24S,25R diastereoisomers and in the absence of authentic stan-
dards for each compound we cannot be sure which isomer is present in
plasma. Our data, however, showing a degree of enrichment of deu-
terium of only 20% does suggest that the majority of the acid is derived
from brain and is thus the 7α,24S-diH,3O-CA(25R) diastereomer. This
is supported by the abundant co-eluting peak in the chromatogram
from plasma of the CYP46A1tg mouse where the CYP46A1 protein is
abundant in brain [53].
There are two other minor dihydroxyoxocholestenoic acids evident
in plasma, one of which eluting at 2.13min (Fig. 5) is the most abun-
dant dihydroxyoxocholestenoic acid found in CSF [72] and annotated,
based on its MS3 spectrum, and in the absence of authentic standards, as
7α,x-dihydroxy-3-oxocholest-4-en-26-oic acid (7α,x-diH,3O-CA),
where x is probably 22, 23 or perhaps 27. Triple deuteration rules out
the possibility of the additional hydroxyl group on C-27. The second
minor dihydroxyoxocholestenoic elutes at 3.8min and corresponds to
Fig. 4. Enrichment of deuterium in cholestenoic acids and some minor oxysterols. (A) RICs for the [M]+ ions of [2H0] (m/z 553.4161, upper panel), [2H3] (m/z
556.4349, central panel), [2H6] (m/z 559.4537, lower panel) corresponding to 3β-HCA and to 3β,x-diHC-yO+x-HC-3,y-diO. (B) RICs for the [M]+ ions of [2H0] (m/
z 569.4110, upper panel), [2H3] (m/z 572.4298, central panel), [2H6] (m/z 575.4486, lower panel) corresponding to 7αH,3O-CA, 3β,7β-diHCA and to 3β,x,y-triHC-
zO. See Supplemental Fig. S4 for MS3 spectra.
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one of the diasterioisomers of 7α,25-dihydroxy-3-oxocholest-4-en-26-
oic acid [72] (7α,25-diH,3O-CA). The degree of enrichment of deu-
terium for these two minor components was found to be 40%–60%
indicating that they are not formed behind the BBB.
As illustrated in Fig. 3, the pathways starting with 7α-, (25R)26- and
24S-hydroxylation of cholesterol converge at 7α-hydroxy-3,24-bisox-
ocholest-4-en-(25R)26-oic acid (7αH,3,24-diO-CA) [71,73]. 7αH,3,24-
diO-CA is unstable and will decarboxylate to 7α-hydroxy-26-norcholest-
4-ene-3,24-dione (7αH,26-nor-C-3,24-diO) [19,74]. The degree of
enrichment of deuterium of 7αH,26-nor-C-3,24-diO was found to be
50%, a value intermediate between that for 7α,24S-diH,3O-CA(25R),
i.e. 20%, and the 25R and 25S epimers of 7αH,3O-CA, i.e. 60–65%. This
is entirely consistent with the notion that the cholestenoic acid content
of plasma reﬂects the diﬀerent pathways of bile acid biosynthesis, both
hepatic and non-hepatic [41].
Fig. 5. The degree of enrichment of deuterium in 7α,24S-diH,3O-CA is less than in 7α,12α-diH,3O-CA. (A) RICs for the [M]+ ions of [2H0] (m/z 585.4059, upper
panel) and [2H3] (m/z 588.4247, lower panel) dihydroxy-3-oxocholest-4-en-26-oic acids (diH,3O-CA). (B) TICs for the [M]+→ [M-Py]+→ transitions for [2H0]
(585.4→501.3→, upper panel) and [2H3] (588.4→504.4→) appropriate to diH,3O-CA. (C) MRM transitions [M]+→ [M-Py]+→[M-Py-CO-CO2H2] for [2H0] (585.4→
501.3→427.3, upper panel) and [2H3] (588.4→504.4→430.4, lower panel) isotopologues targeting diastereoisomers of 7αH,24-diH,3O-CA [72]. (D) MRM transi-
tions [M]+→[M-Py]+→[M-Py-NHCO-H2O]+ for [2H0] (585.4→501.3→440.3, upper panel) and [2H3] (588.4→504.4→443.3, lower panel) isotopologues targeting
diastereoisomers of 7α,x-diH,3O-CA. (E) MRM transitions [M]+→[M-Py]+→[M-Py-H2CO2]+ for [2H0] (585.4→501.3→455.3, upper panel) and [2H3] (588.4→
504.4→458.3, lower panel) isotopologues targeting diastereoisomers of 7αH,25-diH,3O-CA. Note the targeting transitions are not unique to the targeted species. MS3
spectra are shown in Supplemental Fig. S6.
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3.2. Oxysterols and cholestenoic acids in the CYP46A1tg mouse
In the WT mouse, both 24S-HC and 24R-HC epimers are present in
plasma, the 24S-epimer being about ﬁve times more abundant than the
R-epimer, when measured after saponiﬁcation of oxysterol esters [28].
As discussed above, in mouse 24S-HC observed in the circulation is
formed predominantly in brain but also to a minor extent extra-cere-
brally, while 24R-HC is formed extra-cerebrally but is also present at
low levels in brain, perhaps originating from the circulation [75–77]. In
human, 24R-HC is barely detectable in the circulation and has not yet
been reported to be present in brain where 24S-HC is the dominant
oxysterol [78].
In the CYP46A1tg mouse, human CYP46A1 is expressed under
control of the β-actin promoter [53]. The protein is found mostly in
brain, but also to a minor extent (10% cf. brain 100%) in eye and testis,
two other organs separated from the circulation by barriers akin to the
BBB [53]. In the WT mouse CYP46A1 protein is found in testis but not
eye [53]. The CYP46A1tg mouse provides an excellent model to deﬁne
cholesterol metabolites synthesised behind these barriers, pre-
dominantly from brain, adding further insight to the mechanistic pro-
posals made above.
We have previously analysed the 24R/S-HC content of plasma from
the CYP46A1tg mouse after base hydrolysis of oxysterol esters [28]. We
found the concentration of 24S-HC to be almost doubled compared to
the WT mouse but that of 24R-HC to be increase by only one third. This
indicates a higher ﬂux of 24S-HC into the circulation from the mutant
mouse, although part of the increase in 24S-HC and 24R-HC may be
from extracerebral tissue [28]. We have now extended this earlier study
to investigate non-esteriﬁed oxysterols (measured in the absence of
base hydrolysis).
3.2.1. Oxysterols
A limitation of the current study is that plasma from only two
transgenic animals was analysed, hence the data should be regarded as
“proof of principle”. Despite this limitation, the concentration of 24S-
HC was found to be elevated by factors of three and seven in the two
CYP46A1tg mice over the wild-type mouse with the highest con-
centration of 24S-HC (Fig. 7, Supplemental Table S3). In the two CY-
P46A1tg mice the 24R-HC epimer contributed 2–3% of the total 24-HC
concentration; in comparison in the three WT mice the 24R-HC epimer
contributed 15–20% to the total 24-HC. This data agrees with that
obtained by Saeed et al for 24-HC following saponiﬁcation of oxysterol
esters, conﬁrms that the majority of 24S-HC is from cerebral tissue and
suggests that most 24R-HC is generated by an enzyme other than
CYP46A1 [28]. Importantly, Meljon et al have shown that 24R-HC is
present in brain of the Cyp46a1-/- mouse adding weight to the sug-
gestion that its biosynthesis is independent of CYP46A1 [75].
Of the other oxysterols, the concentration of 24S,25-EC was found
to be increased in the CYP46A1tg mice. Using EADSA technology
24S,25-EC is unstable being hydrolysed to 24,25-dihydroxycholesterol
(24,25-diHC), undergoing methanolysis to 24-hydroxy,25-methox-
ycholesterol (24H,25OMe-C), both in acid catalysed reactions with
solvent, and isomerisation to 24-oxocholesterol (24-OC). Taking total
24S,25-EC to be the sum of remaining unreacted 24S,25-EC and these
three products, the plasma concentrations of total 24S,25-EC were
factors of two and four greater in the CYP46A1tg mice than in the WT
mouse with highest 24,25-EC concentration (Supplementary Table 3).
We have previously reported a similar elevation in 24S,25-EC in brain
of CYP46A1tg embryos and adults [79]. When broken down into the
component elements unmodiﬁed 24S,25-EC increased by factors of
about ﬁve and ten, 24-OC by factors of about two and three, and the
hydrolysis products by factors of about two and four over the WT mice
with highest concentration of these molecules (Figs. 7 and 8). The
concentration of the methanolysis product increased in only one of the
mice, by a factor of 1.3 over the WT mouse with highest concentration
of 24H,25OMe-C. It should be noted 24,25-diHC could be formed also
by CYP46A1 oxidation of cholesterol [80]. The likely metabolic route of
24S,25-EC is 7α-hydroxylation by CYP7B1, as the plasma concentration
of 24S,25-EC is elevated in the CYP7b1-/- mouse [76].
CYP39A1 is the dominant 24S-hydroxycholesterol 7α-hydroxylase
[81]. 7α,24S-Dihydroxycholesterol (7α,24S-diHC) is metabolised fur-
ther by HSD3B7 to give 7α,24S-dihydroxycholest-4-en-3-one (7α,24S-
diHCO). In our chromatographic system the ﬁrst peaks of 7α,24S-di-
hydroxysterols almost co-elute with their 7α,25-dihydroxy-isomers but
the less intense second peaks of the syn and anti conformers are re-
solved, allowing deconvolution of relative abundance (Fig. 8). Peaks
corresponding to 7α,24S-diHCO and 7α,25-diHCO are observed in both
genotypes. The peaks corresponding to 7α,24S-diHCO were elevated in
the two transgenic mice by factors of about ten above the levels in the
WT animals, while there was little diﬀerence in 7α,25-diHCO or 7α,26-
diHCO concentrations in the two genotypes. The levels of the dihy-
droxycholesterols were near or below the limit of detection of our
analytical method.
Of the other oxysterols analysed in this study, the concentrations of
25-HC and 26-HC increased in only one of the CYP46A1tg animals,
while the concentrations of 7α-HC, 7β-HC, 7-OC and 6-hydro-
xycholesterol (6-HC) did not diﬀer between genotypes. 7β-HC, 7-OC
and 6-HC, which is a dehydration product of cholestane-3β,5α,6β-triol
formed from 5,6-EC by cholesterol epoxide hydrolase [82], are derived
through both enzymatic and non-enzymatic reactions. Interestingly, the
concentrations of 7α-HCO in the CYP46A1tg mice were about half those
in the WT mouse with the lowest plasma concentration. 7α-HCO is a
plasma marker for CYP7A1 activity, and its reduced level in the CY-
P46A1tg mouse is consistent with reduced expression of Cyp7a1 in liver
of this mouse observed by Shafaati et al [53].
With respect to the oxysterols only partially identiﬁed and anno-
tated as 3β,x-diHC-yO, x-HC-3,y-diO and 3β,x,y-triHC-zO, there is no
increase in plasma concentration in the CYP46A1tg mouse indicating
that side-chain hydroxylation is not through CYP46A1.
3.2.2. Cholestenoic acids
We discussed above how plasma from the CYP46A1tg mouse was
used to identify 7α,24S-diH,3O-CA in the mouse fed deuterated cho-
lesterol. This acid is metabolised further to the CoA-thioester of
7αH,3,24-diO-CA (Fig. 3) which under our analytical system is unstable
and decomposes by decarboxylation to 7αH-26-nor-C-3,24-diO. In the
WT mouse this is just a minor metabolite but is elevated by a factor of
about two and six in the two transgenic animals.
Interestingly, the abundance of the acid identiﬁed as 7α,12α-
diH,3O-CA was reduced in the transgenic animals. This agrees with the
pathway which proceeds through 7α-HC and 7α-HCO and the data
from Shafaati et al indicating the expression in liver of Cyp7a1 is
Fig. 6. Dihydroxyoxocholestenoic acids in plasma of the CYP46A1tg mouse. (A) RICs for the [M]+ ions, m/z 585.4059, of dihydroxy-3-oxocholest-4-en-26-oic acids
(diH,3O-CA) from a CYP46A1tg (upper panel) and WT (lower panel) mouse. (B) TICs for the [M]+→[M-Py]+→ transitions, 585.4→501.3→, appropriate to diH,3O-
CA from a CYP46A1tg (upper panel) and WT (lower panel) mouse. (C) MRM transitions [M]+→[M-Py]+→[M-Py-CO-CO2H2], 585.4→501.3→427.3, targeting
diastereoisomers of 7α,24-diH,3O-CA, from a CYP46A1tg (upper panel) and WT (lower panel) mouse. (D) MRM transitions [M]+→[M-Py]+→[M-Py-H2CO2]+,
585.4→501.3→455.3, targeting diastereoisomers of 7α,25-diH,3O-CA, from a CYP46A1tg (upper panel) and WT (lower panel) mouse. (E) As in (D) with a retention-
time window 2.4–5.4 min. (F) MRM transitions [M]+→[M-Py]+→[M-Py-CONH-(H2O)2]+, 585.4→501.3→422.3, targeting 7α,12α-diH,3O-CA, from a CYP46A1tg
(upper panel) and WT (lower panel) mouse. (G) As in (F) with a retention-time window 2.4–5.4 min. Note the targeting transitions are not unique to the targeted
species. The chromatograms shown on the expanded scale have been smoothed. See Supplemental Fig. S7 for fragmentation patterns of dihydroxy-3-oxocholest-4-en-
26-oic acids. MS3 spectra are shown in Supplemental Fig. S8.
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reduced in the CYP46A1tg mouse [53]. The plasma concentration of
7α,x-diH,3O-CA, where x is probably 22, 23 or perhaps 27, is reduced
in the CYP46A1tg arguing against an involvement of CYP46A1 in side-
chain hydroxylation.
Of the other cholestenoic acids 7α,25-diH,3O-CA, 3β,7α-diHCA,
7αH,3O-CA and 3β-HCA there were no obvious diﬀerences in plasma
concentrations between the transgenic and WT animals.
4. Discussion
In the current study we have utilised two mouse models to in-
vestigate the origins of oxysterols and cholestenoic acids found in the
circulation. Our intention in this study was to identify minor metabolic
pathways, without evaluating their importance. Higher numbers of
animals will be required to evaluate the signiﬁcance of the metabolic
pathways uncovered. With the ﬁrst mouse model, pdgfbret/ret, we in-
vestigated the degree of enrichment of deuterium of plasma sterols after
40 days of treatment of a single male animal with
[26,26,26,27,27,27-2H6] cholesterol. After 40 days the amount of
deuterated cholesterol was 70% of the total cholesterol in this mouse
[28]. The pdgfbret/ret mouse is a pericyte-deﬁcient mouse model pre-
senting with enhanced BBB permeability. The advantage of this model
is that it expedites the measurement of brain derived cholesterol me-
tabolites in plasma. A disadvantage is the import of a small amount of
cholesterol from the circulation into brain will result in some increased
deuterium content of brain-derived cholesterol metabolites [28]. In
fact, in our earlier study [28], the incorporation of deuterium in brain
cholesterol after 40 days of feeding of the mouse was only about 7%,
corresponding to replacement of about 10% of brain cholesterol with
plasma cholesterol under the conditions used. A second disadvantage of
this model is that there is increased vascular permeability not only in
the brain but also in the liver. The lipoprotein pattern in the circulation
is abnormal with low levels of HDL [28]. The use of the second mouse
model, CYP46A1tg, where human CYP46A1 is expressed under control
of the β-actin promoter with high CYP46A1 protein expression in brain
[53], allowed the deﬁnition of oxysterols derived from CYP46A1 ac-
tivity. A limitation of this study is that only two CYP46A1tg animals
were investigated, however, this did not obscure obvious diﬀerences in
the oxysterol content of plasma between CYP46A1tg and WT mice.
As expected, the degree of enrichment in deuterium of 24S-HC
found in plasma was much lower than of any other oxysterol. This
agrees with earlier studies investigating 24S-HC plasma concentrations
following saponiﬁcation of oxysterol esters [27,28]. The degree of en-
richment of deuterium in our study was about 10%. When the degree of
enrichment of deuterium of plasma cholesterol of 70% is considered a
corrected value of about 15% is obtained. This low degree of enrich-
ment of deuterium compared to corrected values of about 100% for
liver derived 7α-HC and 7α-HCO is explained by the biosynthesis of
24S-HC from a pool of cholesterol isolated from the circulation by the
BBB. The degree of enrichment of deuterium of 15% is artiﬁcially high
on account of some leakage over the pericyte deﬁcient BBB of deuter-
ated cholesterol, estimated to be about 10% in the earlier study of
Saeed et al [28]. The remaining source of deuterated 24S-HC is likely to
be extra-cerebral [27]. CYP46A1 is known to be the dominant choles-
terol 24S-hydroxylase [34]. This is conﬁrmed here by experiments with
the CYP46A1tg mouse where the plasma content of 24S-HC increased
by a factor of at least three over the WT. The concentration of 24R-HC
did not diﬀer between genotypes.
The CYP46A1tg mouse model provided more information on the
origin of 24S,25-EC, where the plasma content was more than double
that in the WT mouse. This can be interpreted by either its direct bio-
synthesis from desmosterol via CYP46A1 [36] or via the shunt pathway
[37], up-regulated as a consequence of increased cholesterol metabo-
lism by CYP46A1 in brain.
Cholestenoic acids are acidic oxysterols formed by the further
CYP27A1 oxidation of a terminal primary alcohol on the sterol side-
chain to a carboxylic acid. Their synthesis from
[26,26,26,27,27,27-2H6]cholesterol is attenuated as a consequence of
the H/D-isotope eﬀect, a result of the enhanced strength of the C–D
bond. The H/D-isotope eﬀect is also evident in 26-HC where the degree
of enrichment of deuterium was measured to be about 50% and cor-
rected to about 70% if circulating cholesterol was 100% deuterated.
These values are exaggerated for 3β-HCA where three deuterium atoms
are removed from [2H6]cholesterol, giving values at about 30% and
corrected to 40% if cholesterol were fully deuterated. Informatively, the
degree of enrichment of deuterium of 7α,26-diHCO, 7αH,3O-CA and
7α,12α-diH,3O-CA is much higher with corrected values of about
95–100%, more in line with values for liver derived 7α-HC and 7α-
HCO. This indicates that 7α,26-diHCO, 7αH,3O-CA and 7α,12α-
diH,3O-CA must be formed from a diﬀerent pool of cholesterol than 26-
HC and 3β-HCA and/or their mechanism of formation does not involve
the removal of deuterium in the rate determining step (Fig. 3) [83].
This data for mouse is in good general agreement to that found when a
similar deuterium enrichment strategy was employed in man [26].
Meaney et al suggested that in man, liver derived 7α-HC provides the
substrate to generate 7α-HCO and subsequently 7αH,3O-CA, while
pulmonary derived 3β-HCA provides the substrate to generate 3β,7α-
diHC. 26-HC was interpreted to be derived from a third pool of cho-
lesterol [26]. A diﬀerence between mouse and man is that 3β,7α-diHCA
is essentially absent from mouse plasma, its likely metabolic route being
to 7αH,3O-CA accounting for the small decrease in deuterium content
of 7αH,3O-CA compared to 7α-HC, 7α-HCO and 7α,26-diHCO.
24S-HC is metabolised by CYP39A1 to 7α,24S-diHC and then to
7α,24S-diHCO. Cyp39a1 is broadly expressed, including expression in
brain and liver, while Hsd3b7, the gene encoding 3β-hydroxy-Δ5-steroid
oxidoreductase is ubiquitously expressed [84]. The concentration of
7α,24S-diHCO is elevated in plasma of the CYP46A1tg mouse as is 7αH-
26-nor-C-3,24-diO derived from 7αH,3,24-diO-CA by decarboxylation
[74], although the concentration of 7α,24S-diH,3O-CA was elevated in
only one of the two CYP46A1tg animals. These three metabolites sit in a
pathway from 24S-HC to bile acids, 7αH,3,24-diO-CA, activated as the
CoA thioester, undergoing side-chain shortening in a reaction catalysed
by sterol carrier protein x in the peroxisome (SCPx or sterol carrier
protein 2, Fig. 3). 7α,24S-diHCO is of low concentration in plasma of
WT mice disallowing measurements of enrichment of deuterium,
however, the degree of enrichment of deuterium of 7α,24S-diH,3O-CA
was only 20%, corrected to 30% for 100% deuterated cholesterol,
suggesting most of its synthesis is from a pool of cholesterol diﬀerent to
7αH,3O-CA and 7α,12α-diH,3O-CA i.e. a pool behind the BBB in brain.
Another source of 7α,24S-diH,3O-CA, independent of 24S-HC, is
through the action of ACOX2 and LBP rather than DBP on 7αH,3O-CA
and this may account for a proportion of the formation of 7α,24S-
Fig. 7. 24S-HC and 24S,25-EC are elevated in plasma from a CYP46A1tg mouse. (A) RICs for the [M]+ ions of monohydroxycholesterols (m/z 539.4368) from a
CYP46A1tg mouse (upper panel) and a WT mouse (lower panel). (B) TICs for the [M]+→[M-Py]+→ transitions for monohydroxycholesterols from the CYP46A1tg
mouse (upper panel) and a WT mouse (lower panel). (C) MRM transitions [M]+→[M-Py]+→353.3 targeting 24-HC epimers (see Supplemental Scheme S3) from a
CYP46A1tg mouse (upper panel) and a WT mouse (lower panel). (D) As in (C) displaying the retention-time window 6–9min. (E) RICs for the [M]+ ions of
24H,25OMe-C (m/z 569.4474) from the CYP46A1tg mouse (upper panel) and a control mouse (lower panel). (F) RICs for the [M]+ ions of m/z 537.4212 corre-
sponding to 24S,25-EC and isomers thereof from the CYP46A1tg mouse (upper panel) and a control mouse (lower panel). (G) TICs for the [M]+→[M-Py]+→
transitions for 24S,25-EC, 24-OC and 26-HD from the CYP46A1tg mouse (upper panel) and a WT mouse (lower panel). MS3 spectra are shown in Supplemental Fig.
S9. Shown in Supplemental Fig. S10 is a scheme depicting isomerisation, hydrolysis and methanolysis of 24S, 25-EC.
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diH,3O-CA. The degree of enrichment of deuterium of 7αH-26-nor-C-
3,24-diO, derived from 7αH,3,24-diO-CA by decarboxylation, was 50%
corrected to 70%, considerably lower than that of 7αH,3O-CA but
somewhat higher than 7α,24S-diH,3O-CA, this is perfectly compatible
with the multiple metabolic pathways converging at 7αH,3,24-diO-CA
during bile acid biosynthesis (Fig. 3).
Besides the oxysterols and cholestenoic acids discussed above sev-
eral other sterol metabolites were partially identiﬁed or identiﬁed and
not quantiﬁed. 20R,22R-Dihydroxycholesterol (20R,22R-diHC) and
surprisingly, 20R,22R-dihydroxycholest-4-en-3-one (20R,22R-diHCO),
as 20R,22R-diHC is not a substrate for HSD3B7, fall into the latter ca-
tegory, as does 26E-hydroxydesmosterol. Relative, rather than absolute
quantiﬁcation was performed on 25-hydroxyvitamin D3 in the absence
of an isotope-labelled authentic standard, while 3β,x-dihydroxycholest-
y-one and x-hydroxycholest-3,y-dione, where x and y are probably 20
and 22, or 22 and 24; 3β,x,y-trihydroxycholest-5-en-z-one where x, y
and z are probably 22, 25 and 24 and 7α,x-dihydroxy-3-oxo-cholest-4-
en-26-oic acid, were partially identiﬁed in the absence of authentic
standards.
5. Conclusions
There are limitations to the current study. Speciﬁcally, only one
animal was treated with [2H6]cholesterol for 40 days and plasma from
only two CYP46A1tg animals was analysed. It may also be argued that
there are shortcomings in using the the pdgfbret/ret mouse model with a
leaky BBB resulting in artiﬁcially high degrees of enrichment of deu-
terium of brain derived metabolites found in plasma. The counter ar-
gument is that to detect deuterated molecules in plasma, a suﬃcient
amount (pmol/mL) must be available. Never-the-less the results from
the experiments with deuterated cholesterol are readily explained
based on our current knowledge of 24S-HC metabolism in mouse. The
use of only two CYP46A1tg animals is not ideal. However, our results
are only interpreted where both mice give the same direction of change
in terms of metabolite concentration. Admittedly, subtler diﬀerences
between CYP46A1tg and WT animals will be lost.
Despite these reservations, the current study conﬁrmed a pathway
from 24S-HC towards bile acids, demonstrated the non-cerebral
CYP46A1-indipendent biosynthesis of 24R-HC and supported the ex-
istence of diﬀerent pathways for the formation of 3β-HCA and 7αH,3O-
CA.
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